Develops cell therapies for inflammatory conditions and heart diseases.
Jun 2025Revenue $17.2M/yrExpenses $119M/yr
No trend
Figures by year
When will Mesoblast be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2025, revenue was $17.2M and expenses $119M.
| Fiscal year to | Revenue | Expenses | Pre-tax profit |
|---|---|---|---|
| Jun 2025 | $17.2M | $119M | −$102M |
| Jun 2024 | $5.90M | $94.0M | −$88.1M |
| Jun 2023 | $7.50M | $89.6M | −$82.1M |
| Jun 2022 | $10.2M | $102M | −$91.6M |
| Jun 2021 | $7.43M | $107M | −$99.6M |
| Jun 2020 | $32.2M | $120M | −$87.4M |
| Jun 2019 | $16.7M | $115M | −$98.8M |
| Jun 2018 | $17.3M | $83.3M | −$66.0M |
| Jun 2017 | $2.41M | $92.6M | −$90.2M |
| Jun 2016 | $42.5M | $133M | −$90.8M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.